{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T10:15:04Z","timestamp":1794132904605,"version":"4.8.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1038\/s41375-024-02175-0","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T11:04:24Z","timestamp":1708427064000},"page":"762-768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9652","authenticated-orcid":false,"given":"Shai","family":"Shimony","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan Philipp","family":"Bewersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8542-2944","authenticated-orcid":false,"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva J.","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3983-5908","authenticated-orcid":false,"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Coleman","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ramos Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2566-3145","authenticated-orcid":false,"given":"Donna S.","family":"Neuberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-2633","authenticated-orcid":false,"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"2175_CR1","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"2175_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"2175_CR3","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS Granfeldt \u00d8stg\u00e5rd","year":"2015","unstructured":"Granfeldt \u00d8stg\u00e5rd LS, Medeiros BC, Sengel\u00f8v H, N\u00f8rgaard M, Andersen MK, Dufva IH, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33:3641\u20139.","journal-title":"J Clin Oncol"},{"key":"2175_CR4","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367\u201376.","journal-title":"Blood"},{"key":"2175_CR5","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1182\/bloodadvances.2019001349","volume":"4","author":"C Gardin","year":"2020","unstructured":"Gardin C, Pautas C, Fournier E, Itzykson R, Lemasle E, Bourhis J-H, et al. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Adv. 2020;4:1942\u20139.","journal-title":"Blood Adv"},{"key":"2175_CR6","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2175_CR7","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2175_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, Dinardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2175_CR9","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684\u201392.","journal-title":"J Clin Oncol"},{"key":"2175_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"2175_CR11","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","volume":"5","author":"EM Cherry","year":"2021","unstructured":"Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021;5:5565\u201373.","journal-title":"Blood Adv"},{"key":"2175_CR12","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","volume":"6","author":"AH Matthews","year":"2022","unstructured":"Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022;6:3997\u20134005.","journal-title":"Blood Adv"},{"key":"2175_CR13","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood.2022;140:1200\u201328.","journal-title":"Blood."},{"key":"2175_CR14","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1182\/blood-2022-169509","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Pratz KW, DiNardo CD, Jonas BA, Pullarkat VA, Thirman MJ, et al. ELN risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine. Blood. 2022;140:1441\u20134.","journal-title":"Blood"},{"key":"2175_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2307\/2530904","volume":"40","author":"CL Link","year":"1984","unstructured":"Link CL. Confidence intervals for the survival function using Cox\u2019s proportional- hazard model with covariates. Biometrics. 1984;40:601\u20139.","journal-title":"Biometrics"},{"key":"2175_CR16","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/ajh.26991","volume":"98","author":"AH Matthews","year":"2023","unstructured":"Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, et al. Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. Am J Hematol. 2023;98:1254\u201364.","journal-title":"Am J Hematol"},{"key":"2175_CR17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.26061","volume":"96","author":"A Maiti","year":"2021","unstructured":"Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, et al. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment\u2010related mortality. Am J Hematol. 2021;96:282\u201391.","journal-title":"Am J Hematol"},{"key":"2175_CR18","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/bloodadvances.2020004173","volume":"5","author":"CA Lachowiez","year":"2021","unstructured":"Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, et al. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 2021;5:2173\u201383.","journal-title":"Blood Adv"},{"key":"2175_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ccell.2022.12.002","volume":"41","author":"E Wang","year":"2023","unstructured":"Wang E, Pineda JMB, Kim WJ, Chen S, Bourcier J, Stahl M, et al. Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia. Cancer Cell. 2023;41:164\u201380.e8.","journal-title":"Cancer Cell"},{"key":"2175_CR20","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood.2023020649","volume":"142","author":"J Senapati","year":"2023","unstructured":"Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, et al. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 2023;142:1647\u201357.","journal-title":"Blood"},{"key":"2175_CR21","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood-2023-173935","volume":"142","author":"S Shimony","year":"2023","unstructured":"Shimony S, Garcia JS, Keating J, Chen EC, Luskin MR, Stahl M, et al. Molecular ontogeny in AML Is both prognostic and predictive in patients treated with hypomethylating agents plus venetoclax. Blood. 2023;142:977.","journal-title":"Blood"},{"key":"2175_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD Dinardo","year":"2020","unstructured":"Dinardo CD, Tiong IS, Quaglieri A, Macraild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791\u2013803.","journal-title":"Blood"},{"key":"2175_CR23","doi-asserted-by":"publisher","first-page":"E171","DOI":"10.1002\/ajh.26146","volume":"96","author":"BJ Ball","year":"2021","unstructured":"Ball BJ, Hsu M, Devlin SM, Arcila M, Roshal M, Zhang Y, et al. The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy. Am J Hematol. 2021;96:E171\u20135.","journal-title":"Am J Hematol"},{"key":"2175_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022;7:51.","journal-title":"Signal Transduct Target Ther"},{"key":"2175_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00277-021-04693-8","volume":"101","author":"O Pasvolsky","year":"2021","unstructured":"Pasvolsky O, Shimony S, Ram R, Shimoni A, Shargian L, Avni B, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. Ann Hematol. 2021;101:379\u201387.","journal-title":"Ann Hematol"},{"key":"2175_CR26","doi-asserted-by":"publisher","first-page":"694.e1","DOI":"10.1016\/j.jtct.2022.07.022","volume":"28","author":"AC Winters","year":"2022","unstructured":"Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, et al. Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax + azacitidine versus intensive chemotherapy. Transpl Cell Ther. 2022;28:694.e1\u2013e9.","journal-title":"Transpl Cell Ther"},{"key":"2175_CR27","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1182\/bloodadvances.2022009632","volume":"7","author":"NJ Short","year":"2023","unstructured":"Short NJ, Ong F, Ravandi F, Nogueras Gonzalez GM, Kadia TM, Daver NG, et al. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv. 2023;7:3573\u201381.","journal-title":"Blood Adv"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02175-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02175-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02175-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T15:03:30Z","timestamp":1712329410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02175-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2175"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02175-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS, JPB, YL, EJS, GM, JRP, and BB have no disclosure. RMS (Yale) reports consultancy for BMS, Curio Science, Gilead, Servier, Rigel. AMZ reports consultancy and Honoraria for Abbvie, Pfizer, Celgene\/BMS, Jazz, Incite, Agios, Servier, Boehringer-Ingelheim, Novartis, Astellas, Daiichi Sankyo, Geron, Taiho, Seattle Genetics, Otsuka, BeyondSpring, Takeda, Ionis, Amgen, Janssen, Genentech, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, Mendus, Zentalis, Schrodinger, Regeneron, Tyme. ADG reports Consultancy for Abbvie, Astellas, Daiichi Sankyo, Genentech; Research funding from Abbvie, Aprea, Aptose, Arog, Celularity, Pfizer, Prelude; Honoraria from Dava Oncology. EMS reports consultancy for Abbvie, Agios, Aptose, Astellas, Blueprint, BMS, Calithera, CTI, DSI, Foghorn Therapeutics, Genentech, Genesis, Gilead, Janssen, Jazz, Menarini, Neoleukin, Novartis, Oncusp, Ono Pharma, PinotBio, Servier, Syndax, Syros, Cellectis, Epizyme, Kura; Research funding from Eisai, BMS; Current equity holder publicly traded company \u2013 Auron therapeutics. ECC reports research funding from Abbvie; Consultancy and Honoraria for Rigel Pharmaceuticals. RCL reports consultancy for Takeda Pharmaceuticals, Bluebird bio, Qiagen, Sarepa Therapeutics, Verve Therapeutics, Jazz Pharmaceuticals, Vertex Pharmaceuticals; Membership on board of directors in Bluebird bio. AS reports Current Employment and Current holder of stock options at Sanofi. DJD reports consultancy for Amgen, Autolus, Blueprint, Gilead, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, and Takeda; received research funding from Abbvie, Novartis, Blueprint and Glycomimetrics. DSN reports equity holder in Madrigal Pharmaceuticals. RMS reports consultancy for Abbvie, CTI Biopharma, GSK, Hermavant, Ligand Pharma, Lava Therapeutics, Amgen, AvenCell, BerGenBio, Cellularity, Jazz, Kura One, Rigel Pharmaecuticals. Serves on safety committee members in Aptevo, Epizyme, Takeda, and Syntrix. MS reports consultancy and serves as a member of the board of directors in Kymera, GSK, and Rigel Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}